�A hallmark of this year's ICAD meeting was the wealth of newfangled clinical trials information in Alzheimer's Disease (AD). Years of basic and presymptomatic research have paved the road for development of new medications and biologics. Results from many unexampled clinical trials were provided, ranging from promising Phase I and II trials to some disappointing Phase II and III results.
Hundreds of new agents for the treatment of dementias ar now in or approaching clinical trials. It is essential that new CNS-drug development in general, and clinical trials specifically, keep pace with the explosive growth in translational opportunities in AD and other CNS disorders. Emergence of novel treatments aimed at disease-progression requires improvements in methodological analysis, particularly in definitions of clinical outcomes, so that health-authorities, patients, physicians, and payers are satisfied.
George Grossberg states: "At the recently over ICAD in Chicago, we witnessed negative results from several large Phase 3 trials of compounds which were touted as potentially having disease-modifying effects for treating AD. Could problems such as those exemplified by these studies get been avoided with better clinical tribulation designs? The ISCTM meetingAdvances in the Conceptualization of Disease Progression in Alzheimer's Disease-An Interdisciplinary Conference, will prove an immensely worthful follow up to ICAD for scientists, clinical trialists, pharmaceutical industry and regulative authorities world-wide who are trying to make our research endeavors more efficient and effective." Ravi Anand and George Grossberg will co-chair the fall ISCTM meeting to pursue this important give-and-take.
The International Society for CNS Clinical Trials and Methodology (ISCTM) will gather world-reknowned experts to talk about challenges identified at ICAD and by others, on October sixty-seven, 2008, in Toronto. Topics to be addressed let in: "Disease Progression in AD," "Optimal Trial-Designs For Disease Modification In AD," "Clinical and Biological Endpoints in Disease Progression/Modification," and "Statistical Issues In Disease-Modifying Therapies In AD Trials." ( Detailed Agenda and Presenters )
Details and Registration (Early Bird rate efficient through Sept 5)
Poster Submission Details
The International Society for CNS Clinical Trials and Methodology (ISCTM) is a multi-disciplinary, self-governing organization devoted to addressing strategic clinical, regulatory, and methodological challenges that arise in the development and clinical enjoyment of CNS therapeutic agents through partnership with industry, academia, governmental and non-governmental agencies and the public.
International Society for CNS Clinical Trials and Methodology
More info
